IgA Nephropathy is referred to being as the utmost causing agent of Glomerulonephritis, which is the inflammation of the glomeruli (part of the kidney that filters blood). IgA antibodies are produced by immune system and act as first line of defense against inhaled and ingested pathogens. IgA Nephropathy is an auto immune disorder caused due to the accumulation of the immunoglobulin A (IgA) which results in inflammation and further damages the glomeruli in kidney. This damage to kidney results in presence of blood and protein in urine, and over time may progress to end-stage renal disease (ESRD).
Researchers have found that, the disease is majorly being observed in the male population as compared to the female population and is specifically prevalent in Asian or Caucasian population. Further, genetic factors also play a key role as a cause of the disease. Researchers believe, that even after a lack of specific treatment for IgA Nephropathy, the process of kidney damage can be slowed down by the use of fish oil supplements, immunosuppressive drugs, corticosteroids angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors.
Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1211
The companies developing the drugs for the treatment of IgA Nephropathy, have shown positive clinical results in the various phases of drug development. For instance, in March 2015, Mallinckrodt plc presented two separate presentations in the U.S. in 2015 Spring Clinical Meetings of the National Kidney Foundation (NKF) and announced the positive results of ACTH (Acthar) Gel, which showed well tolerability and a clinically meaningful response.
Some of the key players involved in the development of the drug candidates for IgA Nephropathy in the late and mid stage include Mallinckrodt plc, Calliditas Therapeutics AB., Anthera Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Merck KGaA, Retrophin Inc., and Omeros Corporation.
IgA Nephropathy Pipeline Analysis
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
This post was originally published on Denton Chronicle